MedTrace Logo

Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain

NCT07532876 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-04-16

No results posted yet for this study

Summary

This study is designed to provide direct evidence on the relative effectiveness and safety of Elagolix versus OCPs, helping physicians make more tailored treatment decisions.

Conditions

  • Endometriosis (Diagnosis)

Interventions

DRUG

Elagolix

Elagolix will be administered at 150 mg once daily in this study.

DRUG

Oral Contraceptive (OC)

In this study, administered once daily in a continuous 28-day cycles for 3 months

Sponsors & Collaborators

  • Pak Emirates Military Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-10-01
Completion
2026-11-01
FDA Drug
Yes

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07532876 on ClinicalTrials.gov